Datum |
Källa |
Rubrik |
Typ |
Alternativ |
2023-08-14 |
Biosergen |
Biosergen AB: Biosergen publishes interim report for first quarter 2023 |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
2023-08-11 |
Biosergen |
Biosergen AB: The subscription price for warrants series TO2 in Biosergen has been determined to SEK 0.66 and the exercise period starts on August 14, 2023 |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
2023-08-11 |
Biosergen |
Biosergen AB: Biosergen publish financial report for second quarter ahead of schedule. |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
Biosergen AB: Biosergen publish financial report for second quarter ahead of schedule.
|
2023-08-07 |
Biosergen |
Biosergen AB: Biosergen Announces Abstract Accepted for Presentation at the 11th Congress on Trends in Medical Mycology (TIMM-11) |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
2023-06-12 |
Biosergen |
Biosergen AB: Biosergen will present at Aktiespararnas Småbolagsdagarna June 13, 2023 |
Pressreleaser |
Visa
Stäng
|
|
2023-05-31 |
Biosergen |
Biosergen AB: Biosergen publishes interim report for first quarter 2023 |
Rapporter |
Ladda ner
|
Visa
Stäng
|
|
2023-05-31 |
Biosergen |
Bulletin from the annual general meeting on 31 May 2023 in Biosergen AB |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
2023-05-10 |
Biosergen |
Biosergen AB: Biosergen publishes 2022 annual report |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
2023-04-28 |
Biosergen |
Notice of annual general meeting in Biosergen AB |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
2023-04-05 |
Biosergen |
Biosergen AB: Biosergen - Reduced risk after positive phase 1-studies - Mangold Insight Analys |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
2023-04-05 |
Biosergen |
Biosergen AB: Biosergen - Minskad risk efter positiva fas 1-studier - Mangold Insight Analys |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
2023-03-31 |
Biosergen |
Biosergen AB: Biosergen publishes interim report for fourth quarter 2022 |
Rapporter |
Ladda ner
|
Visa
Stäng
|
|
2023-03-29 |
Carlsquare |
Carlsquare: Mrkt BUZZ, Biosergen: Plans for speedy development of lead candidate |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
2023-03-29 |
Biosergen |
Biosergen AB: Biosergen provides Phase 2 clinical development strategy update |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
2023-03-28 |
Biosergen |
Biosergen AB: Biosergen will be participating in Investerarträff arranged by Financial Stockholm, March 29 |
Pressreleaser |
Visa
Stäng
|
|
2023-03-21 |
Biosergen |
Biosergen AB: Biosergen will be participating at Mangold Insight Investor Day, March 22 |
Pressreleaser |
Visa
Stäng
|
|
2023-03-21 |
Biosergen |
Biosergen AB: Carlsquare has initiated its coverage of Biosergen |
Pressreleaser |
Visa
Stäng
|
|
2023-03-20 |
Carlsquare |
Carlsquare: Initiation of coverage, Biosergen: Make antifungals great again |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
2023-03-13 |
Biosergen |
Biosergen AB: Positive topline data from phase 1 study of BSG005 shows it is safe and well tolerated. It gives hope for a change in the treatment paradigm of patients with invasive fungal infections. |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
2023-01-24 |
Biosergen |
Biosergen AB: Biosergen - Fungicide with potential - Mangold Insight Analys |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
2023-01-24 |
Biosergen |
Biosergen AB: Biosergen - Svampdödare med potential - Mangold Insight Analys |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
2023-01-16 |
Biosergen |
Biosergen AB: Biosergen completes the first Multiple Ascending Dose (MAD) cohort of BSG005 phase I trial |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
2022-12-12 |
Biosergen |
Biosergen AB: The first volunteer has been dosed in the MAD part of the Phase I trial of BSG005 |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
2022-11-30 |
Biosergen |
Biosergen AB: Biosergen publishes interim report for third quarter 2022 |
Rapporter |
Ladda ner
|
Visa
Stäng
|
|
2022-10-20 |
Biosergen |
Biosergen AB: Biosergen's warrants of series TO2 are admitted to trading |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
2022-10-19 |
Biosergen |
Biosergen AB: Biosergen allocates shares to an underwriter in connection with the completed rights issue |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
2022-10-05 |
Biosergen |
Biosergen AB: Biosergen appoints Mangold Fondkommission to act as a liquidity provider |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
2022-10-04 |
Biosergen |
Biosergen AB: Biosergen announces the outcome in the rights issue |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
2022-09-26 |
Biosergen |
Biosergen AB: Mangold Insight publishes interview with Biosergen's CEO |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
2022-09-22 |
Biosergen |
Biosergen AB: Members of the board of directors and executive management subscribe in ongoing rights issue |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
2022-09-15 |
Biosergen |
Biosergen AB: The subscription period in Biosergen's rights issue starts today |
Pressreleaser |
Visa
Stäng
|
|
2022-09-08 |
Biosergen |
Biosergen AB: Biosergen moves into the MAD (Multiple Ascending Dose) part of its phase I study after 4 cohorts tested in the SAD (Single Ascending Dose) part of the study. |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
2022-09-02 |
Biosergen |
Biosergen AB: Biosergen's Board of Directors decides on a rights issue of units of approximately SEK 60.2 million |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
2022-08-31 |
Biosergen |
Biosergen AB: Biosergen publishes interim report for second quarter 2022 |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
2022-08-31 |
Biosergen |
Biosergen AB: Biosergen receives a loan of SEK 7 million to finance continued development |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
2022-08-26 |
Biosergen |
Biosergen AB: Biosergen completes the third cohort of BSG005 phase I trial |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|